Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.67 USD | -2.72% | -3.66% | +56.46% |
May. 15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
May. 13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+56.46% | 1.71B | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+1.43% | 22.78B | |
-11.04% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating